-
BlueWhale Bio Science Team led by world-renowned immunotherapy pioneers Carl June and James Riley of University of Pennsylvania
-
BlueWhale Bio technology platform aims to bring cell and gene therapy benefits to patients faster and at lower cost
-
Investors include Danaher Ventures, Novalis LifeSciences, Marshall Wace, Hillhouse Capital
PeptiGrowth Inc. is Launching a Novel Synthetic Peptide VEGF-alternative peptide (VEGFR2 agonist)
PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel synthetic peptide called “VEGF alternative peptide (VEGFR2 agonist)” which has equivalent function to recombinant VEGF (Vascular Endothelial Growth Factor). This product will be on the market at the end of September 2023. [Read more…]
The Cultivated B and denovoMATRIX Partner to Bring Cultivated Meats to Commercial-Scale Production Volumes
Burlington, Ontario, & Dresden, Germany, September 05, 2023 – The Cultivated B (TCB) and denovoMATRIX have entered into a collaborative partnership to conduct a feasibility study with implications that enable the scalable, economically viable commercial production of cultivated meats. denovoMATRIX will contribute its microcarrier technology to test the proliferation of suspended cells in TCB’s bioreactors and cell mediums, and its coating technology for functionalizing scaffolding, which enables a structured final cultivated meat product. [Read more…]
Exo Biologic’s Phase 1/2 Trial is 1st MSC-derived Extracellular Vesicle Trial Approved by EMA
July 17, 2023, Liège, Belgium – EXO Biologics SA, a Belgian biotech company committed to developing biopharmaceuticals using Extracellular Vesicles (EVs) to treat rare diseases with high unmet medical needs, received approval from the European Medicines Agency (EMA) for the EVENEW study, enabling site activation in Europe. EVENEW is an adaptive, seamless Phase 1/2 trial assessing the safety and efficacy of intratracheal administration of EXOB-001 in preventing Bronchopulmonary Dysplasia (BPD) in preterm newborns. The EVENEW Study is the first mesenchymal stromal cell (MSC)-derived extracellular vesicles trial approved by the EMA. [Read more…]
Dr. A.J. Mellott, CEO and Co-Founder of Ronawk, Appointed as Director on the Board of the Biomedical Engineering Society (BMES)
Overland Park, KS – Ronawk, a trailblazing biotechnology company committed to advancing next-generation therapies through innovation powered by Roanwk’s Bio-Block™ platform, is delighted to announce that its CEO and Co-Founder, Dr.
A.J. Mellott, has been elected to serve as a Director on the esteemed Board of Directors of the Biomedical Engineering Society (BMES). [Read more…]
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 97
- Next Page »